logo


U.S. FDA Approves OraQuick ADVANCE(R) 12-Month Shelf Life Dating
Wednesday, January 28, 2009 11:56 PM


(Source: BUSINESS WIRE)trackingOraSure Technologies, Inc.

Investor Contact:

Ronald H. Spair

Chief Financial Officer

610-882-1820

investorinfo@orasure.com

or

Media Contact:

Jennifer Moritz

Zer0 to 5ive for OraSure Technologies

917-748-4006

jmoritz@0to5.com

Logo: http://www.orasure.com

OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the United States Food and Drug Administration (FDA) has approved its request for 12-month shelf life from the date of manufacture for its OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test.

The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick ADVANCE(R) test, and represents a six-month increase in shelf life versus current product available on the market. The Company anticipates having the enhanced product available for delivery starting in March 2009.

"The quality and accuracy of our products is our highest priority and these enhancements to our OraQuick ADVANCE(R) product represents years of work to make what we believe is the best product available on the market even better," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "These enhancements will ensure that OraQuick ADVANCE(R) continues to deliver highly accurate results, consistently and in accordance with our FDA approved package insert claims."

OraQuick ADVANCE(R) is the first and only FDA-approved and CLIA- waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens. As the market leader, OraQuick ADVANCE(R) is used extensively throughout the country in public health settings, hospitals, community-based organizations, and physician offices where HIV testing is conducted.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid testing solutions for drugs of abuse and for the detection of antibodies to HIV.

For more information on the Company, please go to www.orasure.com.

(c) 2009 BUSINESS WIRE. Provided by ProQuest LLC. All rights Reserved.

A service of YellowBrix, Inc.



(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

  
Related Press Releases
Advertisement
Popular Articles
Advertisement
Partner Center
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia